Literature DB >> 14975708

In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.

Katsuyoshi Chiba1, Atsushi Sugiyama, Takehiro Hagiwara, Shin-ichi Takahashi, Kiyoshi Takasuna, Keitaro Hashimoto.   

Abstract

The proarrhythmic effects of fluoroquinolone antibacterial agents, sitafloxacin, gatifloxacin and moxifloxacin, were compared using three in vivo models. In the halothane-anesthetized dogs (n=5), intravenous 10-min infusion of gatifloxacin and moxifloxacin (1-3 mg/kg) prolonged the ventricular effective refractory period and the repolarization period to a similar extent, whereas sitafloxacin (1-3 mg/kg) prolonged the former only. No significant change was detected in other cardiovascular parameters. In the chronic complete atrioventricular block dogs (n=4), oral administration of 100 mg/kg of gatifloxacin (2 of 4) and moxifloxacin (3 of 4) induced torsades de pointes, which was not observed by sitafloxacin. In the alpha-chloralose-anesthetized rabbits (n=5), intravenous 20-min infusion of 60 mg/kg of gatifloxacin induced torsades de pointes (1 of 5) in the presence of methoxamine infusion, which was not observed by sitafloxacin or moxifloxacin. Thus, the halothane-anesthetized model is suitable for assessing QT prolongation, whereas the chronic complete atrioventricular block model is sensitive for detecting torsadogenic action of drugs. The alpha-chloralose-anesthetized model is the simplest and least expensive method, but its sensitivity to detect proarrhythmic action may be less great.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975708     DOI: 10.1016/j.ejphar.2003.12.014

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.

Authors:  Xian Chen; Jessica D Cass; Jenifer A Bradley; Corinn M Dahm; Zhuoqian Sun; Edmund Kadyszewski; Michael J Engwall; Jun Zhou
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.

Authors:  Elke Detre; Morten B Thomsen; Jet D Beekman; Karl-Uwe Petersen; Marc A Vos
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

3.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.

Authors:  Akira Takahara; Atsushi Sugiyama; Yuko Ishida; Yoshioki Satoh; Kai Wang; Yuji Nakamura; Keitaro Hashimoto
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 5.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

6.  No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.

Authors:  M B Thomsen; J D M Beekman; N J M Attevelt; A Takahara; A Sugiyama; K Chiba; M A Vos
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

Review 7.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

8.  Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.

Authors:  T Altin; O Ozcan; S Turhan; A Ongun Ozdemir; O Akyurek; R Karaoguz; M Guldal
Journal:  Can J Cardiol       Date:  2007-09       Impact factor: 5.223

Review 9.  Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.

Authors:  M A Vos
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 10.  Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.

Authors:  A Sugiyama
Journal:  Br J Pharmacol       Date:  2008-06-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.